检索
AI 对话
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

Lenvatinib plus pembrolizumab versus sunitinib for advanced renal cell carcinoma: Japanese patients from the CLEAR study.

Masatoshi Eto,Toshio Takagi,Go Kimura,Satoshi Fukasawa,Satoshi Tamada,Yuji Miura,Mototsugu Oya,Naoto Sassa,Satoshi Anai,Masahiro Nozawa,Hideki Sakai,Rodolfo Perini,Wataru Yusa,Hiroki Ikezawa,Tomoyuki Narita,Yoshihiko Tomita

Cancer medicine（2023）

引用 1|浏览19
暂无评分
摘要
These findings support lenvatinib plus pembrolizumab as a potential first-line treatment for Japanese patients with advanced renal cell carcinoma.
更多
查看译文
关键词
CLEAR study,Japanese patients,lenvatinib,pembrolizumab,renal cell carcinoma
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要